Header Logo

Connection

CHARLES CHUANHAI GUO to Middle Aged

Back to Details
This is a "connection" page, showing publications CHARLES CHUANHAI GUO has written about Middle Aged.
CHARLES CHUANHAI GUO
Connection Strength
0.720
Middle Aged
  1. Diagnostic accuracy of upper tract urothelial carcinoma using biopsy, urinary cytology, and nephroureterectomy specimens: A tertiary cancer center experience. Am J Clin Pathol. 2024 Nov 04; 162(5):492-499.
    View in: PubMed
    Score: 0.036
  2. Epithelioid trophoblastic tumor in male patients with germ cell tumor: A clinicopathologic analysis of five cases. Hum Pathol. 2024 Nov; 153:105673.
    View in: PubMed
    Score: 0.036
  3. Plasmacytoid urothelial carcinoma of the urinary bladder-A clinicopathological and molecular analysis of 52 cases. Hum Pathol. 2024 06; 148:1-6.
    View in: PubMed
    Score: 0.035
  4. Distinct Gene Mutations Are Associated With Clinicopathologic Features in Urachal Carcinoma. Am J Clin Pathol. 2022 08 04; 158(2):263-269.
    View in: PubMed
    Score: 0.031
  5. Somatic-type Malignancies in Testicular Germ Cell Tumors: A Clinicopathologic Study of 63 Cases. Am J Surg Pathol. 2022 01 01; 46(1):11-17.
    View in: PubMed
    Score: 0.030
  6. Secondary tumors of the bladder: A survival outcome study. Ann Diagn Pathol. 2020 Oct; 48:151593.
    View in: PubMed
    Score: 0.027
  7. Bladder Cancer Involving Smooth Muscle of Indeterminate Type or Muscularis Mucosae in Transurethral Biopsy Specimens. Am J Clin Pathol. 2020 07 07; 154(2):208-214.
    View in: PubMed
    Score: 0.027
  8. Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer. Cell Rep. 2019 05 07; 27(6):1781-1793.e4.
    View in: PubMed
    Score: 0.025
  9. Small cell carcinoma of the urinary bladder: a clinicopathological and immunohistochemical analysis of 81 cases. Hum Pathol. 2018 09; 79:57-65.
    View in: PubMed
    Score: 0.023
  10. Plasmacytoid Urothelial Carcinoma of the Urinary Bladder: A Clinicopathologic and Immunohistochemical Analysis of 49 Cases. Am J Clin Pathol. 2017 May 01; 147(5):500-506.
    View in: PubMed
    Score: 0.021
  11. Primary Ewing Sarcoma / Primitive Neuroectodermal Tumor of the Kidney: A Clinicopathologic Study of 23 Cases. Pathol Oncol Res. 2018 Jan; 24(1):153-159.
    View in: PubMed
    Score: 0.021
  12. Urachal carcinoma: a pathologic and clinical study of 46 cases. Hum Pathol. 2015 Dec; 46(12):1808-14.
    View in: PubMed
    Score: 0.019
  13. Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variants. Am J Clin Pathol. 2014 Dec; 142(6):864-71.
    View in: PubMed
    Score: 0.018
  14. Sarcomatoid urothelial carcinoma with chondrosarcomatous differentiation of the ureter: a case report. Anal Quant Cytopathol Histpathol. 2014 Apr; 36(2):111-6.
    View in: PubMed
    Score: 0.017
  15. Differential expression of GATA-3 in urothelial carcinoma variants. Hum Pathol. 2014 Jul; 45(7):1466-72.
    View in: PubMed
    Score: 0.017
  16. Relationship between primary and metastatic testicular germ cell tumors: a clinicopathologic analysis of 100 cases. Hum Pathol. 2013 Oct; 44(10):2220-6.
    View in: PubMed
    Score: 0.016
  17. Small cell carcinoma of the kidney: a clinicopathologic study of 14 cases. Hum Pathol. 2011 Nov; 42(11):1792-8.
    View in: PubMed
    Score: 0.015
  18. The relationship of TMPRSS2-ERG gene fusion between primary and metastatic prostate cancers. Hum Pathol. 2012 May; 43(5):644-9.
    View in: PubMed
    Score: 0.014
  19. [TMPRSS2-ERG gene fusion in metastatic prostate cancers: a study of fine needle aspiration specimens]. Zhonghua Bing Li Xue Za Zhi. 2011 Jun; 40(6):392-6.
    View in: PubMed
    Score: 0.014
  20. TMPRSS2-ERG gene fusion in small cell carcinoma of the prostate. Hum Pathol. 2011 Jan; 42(1):11-7.
    View in: PubMed
    Score: 0.014
  21. Testicular germ cell tumors with sarcomatous components: an analysis of 33 cases. Am J Surg Pathol. 2009 Aug; 33(8):1173-8.
    View in: PubMed
    Score: 0.012
  22. Squamous cell carcinoma of the urinary bladder: a clinicopathologic and immunohistochemical study of 16 cases. Hum Pathol. 2009 Oct; 40(10):1448-52.
    View in: PubMed
    Score: 0.012
  23. Prostate cancer of transition zone origin lacks TMPRSS2-ERG gene fusion. Mod Pathol. 2009 Jul; 22(7):866-71.
    View in: PubMed
    Score: 0.012
  24. Micropapillary variant of urothelial carcinoma in the upper urinary tract: a clinicopathologic study of 11 cases. Arch Pathol Lab Med. 2009 Jan; 133(1):62-6.
    View in: PubMed
    Score: 0.012
  25. Prostate cancer invading the rectum: a clinicopathological study of 18 cases. Pathology. 2009; 41(6):539-43.
    View in: PubMed
    Score: 0.012
  26. Tumor-to-tumor metastasis: report of 2 cases of metastatic carcinoma to angiomyolipoma of the kidney. Arch Pathol Lab Med. 2008 Jun; 132(6):1016-20.
    View in: PubMed
    Score: 0.012
  27. Intraductal carcinoma of the prostate on needle biopsy: Histologic features and clinical significance. Mod Pathol. 2006 Dec; 19(12):1528-35.
    View in: PubMed
    Score: 0.010
  28. Noninvasive squamous lesions in the urinary bladder: a clinicopathologic analysis of 29 cases. Am J Surg Pathol. 2006 Jul; 30(7):883-91.
    View in: PubMed
    Score: 0.010
  29. A Pilot Study of the CD38 Antagonist Daratumumab in Patients with Metastatic Renal Cell Carcinoma or Muscle-Invasive Bladder Cancer. Cancer Res Commun. 2024 Sep 01; 4(9):2444-2453.
    View in: PubMed
    Score: 0.009
  30. Loss of LPAR6 and CAB39L dysregulates the basal-to-luminal urothelial differentiation program, contributing to bladder carcinogenesis. Cell Rep. 2024 May 28; 43(5):114146.
    View in: PubMed
    Score: 0.009
  31. Phase 1b Trial Evaluating Tolerability and Activity of Targeted Fibroblast Growth Factor Receptor Inhibition in Localized Upper Tract Urothelial Carcinoma. J Urol. 2024 Jun; 211(6):784-793.
    View in: PubMed
    Score: 0.009
  32. Influence of lamina propria invasion extension on T1 high-grade non-muscle-invasive bladder cancer in patients undergoing BCG or radical cystectomy. BJU Int. 2024 Jun; 133(6):733-741.
    View in: PubMed
    Score: 0.009
  33. Urinary Large Cell Neuroendocrine Carcinoma: A Clinicopathologic Analysis of 22 Cases. Am J Surg Pathol. 2021 10 01; 45(10):1399-1408.
    View in: PubMed
    Score: 0.007
  34. Progression of Disease after Bacillus Calmette-Gu?rin Therapy: Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy. J Urol. 2021 11; 206(5):1258-1267.
    View in: PubMed
    Score: 0.007
  35. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med. 2020 12; 26(12):1845-1851.
    View in: PubMed
    Score: 0.007
  36. Whole-Organ Genomic Characterization of Mucosal Field Effects Initiating Bladder Carcinogenesis. Cell Rep. 2019 02 19; 26(8):2241-2256.e4.
    View in: PubMed
    Score: 0.006
  37. Outcomes of nonmetastatic micropapillary variant upper tract urothelial carcinoma. Urol Oncol. 2019 06; 37(6):354.e19-354.e26.
    View in: PubMed
    Score: 0.006
  38. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign. Eur Urol Oncol. 2019 05; 2(3):286-293.
    View in: PubMed
    Score: 0.006
  39. Impact of High-risk Features and Effect of Neoadjuvant Chemotherapy in Urothelial Cancer Patients with Invasion into the Lamina Propria on Transurethral Resection in the Absence of Deep Muscle Invasion. Eur Urol Focus. 2017 12; 3(6):577-583.
    View in: PubMed
    Score: 0.005
  40. Transformation of prostatic adenocarcinoma to well-differentiated neuroendocrine tumor after hormonal treatment. Hum Pathol. 2017 06; 64:186-190.
    View in: PubMed
    Score: 0.005
  41. Clinical risk stratification in patients with surgically resectable micropapillary bladder cancer. BJU Int. 2017 05; 119(5):684-691.
    View in: PubMed
    Score: 0.005
  42. Meta-Analysis of the Luminal and Basal Subtypes of Bladder Cancer and the Identification of Signature Immunohistochemical Markers for Clinical Use. EBioMedicine. 2016 Oct; 12:105-117.
    View in: PubMed
    Score: 0.005
  43. A Phase l Study of a Tumor-targeted Systemic Nanodelivery System, SGT-94, in Genitourinary Cancers. Mol Ther. 2016 Aug; 24(8):1484-91.
    View in: PubMed
    Score: 0.005
  44. Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Gu?rin Therapy: Implication for Clinical Trial Design. Eur Urol. 2016 11; 70(5):778-785.
    View in: PubMed
    Score: 0.005
  45. Clinical outcomes of cT1 micropapillary bladder cancer. J Urol. 2015 Apr; 193(4):1129-34.
    View in: PubMed
    Score: 0.004
  46. Insulin-like growth factor messenger RNA-binding protein 3 expression helps prognostication in patients with upper tract urothelial carcinoma. Eur Urol. 2014 Aug; 66(2):379-85.
    View in: PubMed
    Score: 0.004
  47. Impact of histological variants on clinical outcomes of patients with upper urinary tract urothelial carcinoma. J Urol. 2012 Aug; 188(2):398-404.
    View in: PubMed
    Score: 0.004
  48. Pathological characteristics of prostate cancer recurrence after radiation therapy: implications for focal salvage therapy. J Urol. 2012 Jul; 188(1):98-102.
    View in: PubMed
    Score: 0.004
  49. Subclassification of pT3 urothelial carcinoma of the renal pelvicalyceal system is associated with recurrence-free and cancer-specific survival: proposal for a revision of the current TNM classification. Eur Urol. 2012 Aug; 62(2):224-31.
    View in: PubMed
    Score: 0.004
  50. Upper urinary tract urothelial carcinoma with loco-regional nodal metastases: insights from the Upper Tract Urothelial Carcinoma Collaboration. BJU Int. 2011 Oct; 108(8):1286-91.
    View in: PubMed
    Score: 0.003
  51. Accelerated disease progression in prostate cancer and bone metastases with platelet-derived growth factor receptor inhibition: observations with tandutinib. Cancer Chemother Pharmacol. 2011 Oct; 68(4):889-96.
    View in: PubMed
    Score: 0.003
  52. Recurrent seminomas: clinical features and biologic implications. Urol Oncol. 2012 Jul-Aug; 30(4):494-501.
    View in: PubMed
    Score: 0.003
  53. Renal epithelioid angiomyolipoma with atypia: a series of 40 cases with emphasis on clinicopathologic prognostic indicators of malignancy. Am J Surg Pathol. 2010 May; 34(5):715-22.
    View in: PubMed
    Score: 0.003
  54. Smooth muscle neoplasms of the urinary bladder: a clinicopathologic study of 51 cases. Am J Surg Pathol. 2010 Apr; 34(4):502-9.
    View in: PubMed
    Score: 0.003
  55. Primary carcinoid tumors of the testis: a clinicopathologic study of 29 cases. Am J Surg Pathol. 2010 Apr; 34(4):519-24.
    View in: PubMed
    Score: 0.003
  56. Primary leiomyosarcoma of the kidney: a clinicopathologic study of 27 cases. Am J Surg Pathol. 2010 Feb; 34(2):238-42.
    View in: PubMed
    Score: 0.003
  57. Tumour necrosis is an indicator of aggressive biology in patients with urothelial carcinoma of the upper urinary tract. Eur Urol. 2010 Apr; 57(4):575-81.
    View in: PubMed
    Score: 0.003
  58. Assessment of the minimum number of lymph nodes needed to detect lymph node invasion at radical nephroureterectomy in patients with upper tract urothelial cancer. Urology. 2009 Nov; 74(5):1070-4.
    View in: PubMed
    Score: 0.003
  59. Tertiary Gleason patterns and biochemical recurrence after prostatectomy: proposal for a modified Gleason scoring system. J Urol. 2009 Oct; 182(4):1364-70.
    View in: PubMed
    Score: 0.003
  60. Ductal adenocarcinoma of the prostate: clinical features and implications after local therapy. Cancer. 2009 Jul 01; 115(13):2872-80.
    View in: PubMed
    Score: 0.003
  61. Impact of lymph node dissection on cancer specific survival in patients with upper tract urothelial carcinoma treated with radical nephroureterectomy. J Urol. 2009 Jun; 181(6):2482-9.
    View in: PubMed
    Score: 0.003
  62. Comparison of oncologic outcomes for open and laparoscopic nephroureterectomy: a multi-institutional analysis of 1249 cases. Eur Urol. 2009 Jul; 56(1):1-9.
    View in: PubMed
    Score: 0.003
  63. Tumour architecture is an independent predictor of outcomes after nephroureterectomy: a multi-institutional analysis of 1363 patients. BJU Int. 2009 Feb; 103(3):307-11.
    View in: PubMed
    Score: 0.003
  64. Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder: a contemporary review of The University of Texas M D Anderson Cancer Center experience. Cancer. 2007 Aug 15; 110(4):764-9.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.